The dysfunctional host response to influenza A H7N9: A potential treatment option?

Critical Care

Volumn 18, Issue 2, 2014, Pages

  Opal, Steven M ^a   Fedson, David S ^b  

^a BROWN UNIVERSITY   (United States)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CD38 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GAMMA INTERFERON; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; METFORMIN; PROTEIN; RESVERATROL; T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AUTACOID;

ADULT RESPIRATORY DISTRESS SYNDROME; BACTERIAL PNEUMONIA; CELL DEATH; CHINA; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLUENZA A; INFLUENZA A H7N9; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H7N9; LYMPHOCYTOPENIA; MORTALITY; NONHUMAN; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; FEMALE; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; MALE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

FEMALE; HUMANS; INFLAMMATION MEDIATORS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; MALE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84899066523     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13839     Document Type: Note

References (15)

1. Wu W, Shi Y, Hainv G, Liang W, Sheng J, Li L. Immune derangement occurs in patients with H7N9 avian influenza. Crit Care 2014, 18:R43.
2. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan J-H, Lu SH, Yang Y-D, Fang Z, Shen Y-Z, Xi X-M, Gu Q, Zhou Z-M, Qu H-P, Yan Z, Li F-M, Zhao W, Gao Z-C, Wang G-F, Ruan L-X, Wang W-H, Ye J, Cao H-F, Li X-W, Zhang W-H, Fang X-C, He J, Liang W-F, Xie J, Zeng M, Wu X-Z, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013, 368:2277-2285. 10.1056/NEJMoa1305584, 23697469.
3. Gao R, Cao B, Hu Y, Feng Z, Wang D, Wanfu H, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Ziang N, Shen Y, Zebao H, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368:1862-1864. 10.1056/NEJMp1304661, 23577629.
4. H7N9 Influenza. [http://www.who.int/influenza/human_animal_interface/influenza_h7n9/Risk_Assessment/en/].
5. Viboud C, Simonsen L. Global mortality of 2009 pandemic influenza A H1N1. Lancet Infect Dis 2012, 12:651-653. 10.1016/S1473-3099(12)70152-4, 22738892.
6. Dawood FS, Iuliano D, Reed C, Cheng P-Y, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Fiekin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz M, Krishnan A, Lal R, Montgomery JM, Molbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YA, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modeling study. Lancet Infect Dis 2012, 12:687-695. 10.1016/S1473-3099(12)70121-4, 22738893.
7. Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. TIM-3 does not act as a receptor for Galectin-9. PLOS Path 2013, 9:e1003253.
8. Fedson DS. How will physicians respond to the next influenza pandemic. Clin Infect Dis 2014, 58:233-237. 10.1093/cid/cit695, 24145877.
9. Fedson DS, Opal SM. The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threat. Hum Vaccin Immunother 2013, 9:1-10. 10.4161/hv.23606, 3667919, 23442580.
10. Dinarello C. Anti-inflammatory agents: present and future. Cell 2010, 140:935-950. 10.1016/j.cell.2010.02.043, 3752337, 20303881.
11. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JCG, Vogel SN. The TLR4 antagonist, Eritoran, protects mice from lethal influenza infection. Nature 2013, 497:498-502. 10.1038/nature12118, 3725830, 23636320.
12. Shi X, Zhou W, Huang H, Zhu H, Zhou P, Zhu H, Dianwen J. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etaneracept provides protection against lethal H1N1 influenza infection in mice. Crit Care 2013, 17:R301. 10.1186/cc13171, 24373231.
13. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013, 99:417-435. 10.1016/j.antiviral.2013.06.018, 23831494.
14. Singla S, Jacobson JR. Statins as a novel therapeutic strategy in acute lung injury. Pulm Circ 2012, 2:397-406. 10.4103/2045-8932.105028, 3555410, 23372924.
15. Lurie N, Maniolo T, Patterson AP, Collins F, Frieden T. Research as a part of the public health emergency response. N Engl J Med 2013, 368:1251-1255. 10.1056/NEJMsb1209510, 23534565.